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Abstract
Background: Neuroinflammation has been proposed as a possible mechanism of brain damage after traumatic
brain injury (TBI), but no consensus has been reached on the most relevant molecules. Furthermore, secondary
insults occurring after TBI contribute to worsen neurological outcome in addition to the primary injury. We
hypothesized that after TBI, a specific pattern of cytokines is related to secondary insults and outcome.
Methods: A prospective observational clinical study was performed. Secondary insults by computerized multimodality
monitoring system and systemic value of different cytokines were collected and analysed in the first week after
intensive care unit admission. Neurological outcome was assessed at 6 months (GOSe). Multivariate projection
technique was applied to analyse major sources of variation and collinearity within the cytokines dataset without
a priori selecting potential relevant molecules.
Results: Twenty-nine severe traumatic brain injury patients undergoing intracranial pressure monitoring were studied.
In this pilot study, we demonstrated that after TBI, patients who suffered of prolonged and severe secondary brain
damage are characterised by a specific pattern of cytokines. Patients evolving to brain death exhibited higher levels of
inflammatory mediators compared to both patients with favorable and unfavorable neurological outcome at 6 months.
Raised ICP and low cerebral perfusion pressure occurred in 21 % of good monitoring time. Furthermore, the principal
components selected by multivariate projection technique were powerful predictors of neurological outcome.
Conclusions: The multivariate projection method represents a valuable methodology to study neuroinflammation
pattern occurring after secondary brain damage in severe TBI patients, overcoming multiple putative interactions
between mediators and avoiding any subjective selection of relevant molecules.
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Background
Neuroinflammation is recognized as a key feature occur-
ring after traumatic brain injury (TBI), and both localized
and systemic inflammatory reactions have been proposed
as potential mechanisms of damage or as putative benefi-
cial responses to injury, depending on timing and severity
[1–7]. Several cytokines, chemokines, and cell adhesion
molecules have been identified in blood, cerebrospinal
fluid (CSF), or brain microdialysate of patients with TBI
with a highly variable profile in terms of peak and dur-
ation [5, 7–10].
After TBI, the injured brain is vulnerable to secondary
damage which may be exacerbated by damaging events
known as secondary insults contributing to worsen neuro-
logical outcome [11–15]. These harmful complications,
occurring both in the prehospital phase and after intensive
care unit (ICU) admission, include hypotension, hypoxia,
high intracranial pressure, and nosocomial infection
whose occurrence can be determined only if rigorously
pursued after TBI [15–19]. The use of a minute by minute
recording of physiological variables with a computerised
multimodality monitoring system [18] can be applied to
investigate basic mechanisms underlying secondary brain
damage. These complications are indicative of secondary
central nervous system (CNS) injury eventually occurring
as a result of prolonged inflammation. Although several
studies [1, 2, 4, 5, 7, 9, 20–23] have investigated the role of
some given cytokines in the pathophysiology of TBI, there
is no consensus on those who may serve as biomarkers of
brain injury. Previous studies separately evaluated the rela-
tionship between selected cytokines and intracranial
hypertension [22], hypoxemia [24], or the prognostic
value of these mediators [25]. Among the main limita-
tions of these studies on neuroinflammation, there are
the multiple putative interactions between mediators
which may vary together after TBI, and the limit of “a
priori” selection of the potential relevant molecules [5,
8, 10]. Multivariate regression techniques are indeed
limited to comparison of multivariate data in a large
number of patients to prevent overfitting.
Multivariate projection methods, such as principal
component analysis (PCA), and partial least squares
(PLS), are data reduction techniques that allow the
major sources of variation in a multi-dimensional
dataset to be analysed avoiding the "a priori" selection
of the potential relevant variables in a relatively small
number of observations. PCA has been first proposed
by Helmy et al. [9] in TBI patients to explore the pat-
tern of production, time profile, and differing patterns
of response of cytokines in brain and peripheral blood
and then by Kumar et al. [5], who studied the prog-
nostic value of a combination of CSF inflammatory
molecules taking into account the variability across
patients.
In the present study, we hypothesised that in patients
with TBI, a specific pattern of cytokines and chemo-
kines is related to secondary insults and may identify
patients who die early because of brain herniation. To
address the issue of mediators covariance we applied
the multivariate projection techniques, including PCA
and PLS analyses.
Methods
Patient population
The Institutional Review Board (Comitato Etico Intera-
ziendale AOU Citta’ della Salute e della Scienza di Torino,
Italy) approved the study protocol. At enrollment, patients
were unconscious and unable to give consent, therefore
the family was informed of the study, and consent was
delayed until the patient was able to provide valid in-
formed consent. Written permission for using collected
data was then obtained from the patient or from the
family (in case of death or if the patient remained in-
competent to give consent). All patients with severe
TBI consecutively admitted to the NeuroICU at the
Azienda Ospedaliera Universitaria Citta’ della Salute e
delle Scienza di Torino were prospectively recruited
over a period of 3 years, according to the following inclu-
sion criteria: age older than 18 years, severe head injury
(Glasgow Coma Score (GCS) < 9) at ICU admission,
placement of intracranial pressure (ICP) monitoring, and
admission within 24 h after injury. Exclusion criteria were:
both pupils fixed and dilated, history of immunosuppres-
sion, pregnancy, and lack of consent.
Clinical management
All the patients were sedated, intubated, mechanically
ventilated, and managed according to the Brain Trauma
Foundation Guidelines [26]. The GCS at the time of ad-
mission was recorded, and the Injury Severity Score
(ISS) was used for the assessment of multiple injuries.
Apache II score (Acute Physiology And Chronic Health
Evaluation) was used for a quantification of the severity
of illness and Marshall scale was used to classify head
CT scan on admission. As part of the clinical manage-
ment mean arterial pressure (MAP), intracranial pres-
sure (ICP), cerebral perfusion pressure (CPP), oxygen
saturation measured by pulse oximetry (SpO2), and
temperature were continuously recorded.
Multimodality monitoring system for secondary insults
detection
A computerized multimodality monitoring system was
used for the collection of physiological parameters. A bed-
side laptop computer with specialized software displayed
and saved one value per minute for each monitored
physiological parameter. For the purpose of the study, data
monitoring was started at the time of ICP placement and
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collected until ICP monitoring was discontinued for clin-
ical reasons. Data were collected as part of a European
network for collection and analysis of higher resolution
data after TBI, the Brain Monitoring with Information
Technology (BrainIT group) [27]. The Odin browser soft-
ware was used for data analysis. Thresholds for secondary
insults were derived from EUSIG [13]. The secondary
insults analysed were raised ICP, low CPP, hypotension,
hypoxia and pyrexia. Secondary insult thresholds, for
grades 1, 2, and 3 were, respectively: ICP ≥ 20, ≥ 30, ≥
40 mmHg for raised ICP insult; CPP ≤ 60, ≤50, ≤40 mmHg
for low CPP insult; MAP ≤ 70, ≤ 55, ≤ 40 mmHg for
hypotension insult; SaO2 ≤ 90, ≤85, ≤ 80 % for hypoxia in-
sult; Temperature ≥ 38, ≥39, ≥ 40 °C for pyrexia insult.
Each derangement had to be sustained for at least 5 min
to be deemed a secondary insult, for 60 min in the case of
pyrexia. The amount of secondary insult was calculated as
the time spent within the insult threshold level divided by
the good monitoring time (GMT) for that patient and
presented as proportion of GMT [13, 18, 28, 29]. GMT is
described as total monitoring time minus invalid monitor-
ing or gaps in data collection for procedures, computerized
tomography (CT) scan or system failures. All monitoring
data were screened manually to disclose artifacts.
Neurological outcome
For evaluation of neurological outcome at 6 months the
Glasgow Outcome Scale-extended (GOSe) was used, with
a score ranging from 1 (death) to 8 (upper good recovery)
[30, 31]. Dichotomization of outcome in favorable (GOSe
5–8) and unfavorable (GOSe1-4) was used; patients evolv-
ing to brain death in the early phase of ICU stay were
identified as a separate group.
Inflammatory mediators analysis
Blood samples for cytokine analysis were collected at
the time of ICP placement (T0), 24 (T1), 48 (T2), and
72 h (T3) later. Samples were centrifuged for 10 min at
3000 RPM at 4 °C and plasma was then frozen at −80 °
C until analysed. The cytokine analysis was performed
with the Bioplex technology (BioRad Laboratories), which
combines the principle of a sandwich immunoassay with
fluorescent bead-based technology [32]. The Bioplex assay
analyses 27 cytokines: Interleukin-1 beta (IL-1β), IL-1
receptor antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-9, IL-10, IL-12 subunit p70 (IL-12p70), IL-13,
IL-15, IL-17, basic Fibroblast growth factor (basic FGF),
eotaxin, granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-
CSF), interferon gamma (IFN-γ), interferon gamma-
induced protein 10 (IP-10), monocyte chemoattractant
protein 1 (MCP-1), macrophage inflammatory protein 1
alpha (MIP-1α), MIP-1β, Platelet-derived growth factor
BB (PDGF-BB), Regulated upon Activation Normal T-cell
Expressed (RANTES), Tumor necrosis factor alpha
(TNF-α), Vascular endothelial growth factor (VEGF)
and was carried out in 96-well microplates using the Bio-
Plex Pro Human Cytokine 27-plex Assay kit following
manufacture instruction (Code M50-0KCAF0Y, Bio-Rad
Laboratories) at the Bioclarma-Research and Molecular
Diagnostics, Torino, Italy. The intra-plate % coefficient of
variance (CV) ranged from 1.11 to 9.96 %, while the inter-
plate % CV ranged from 3 to 11 % for these assays.
All cytokine determinations on plasma samples were
carried out in duplicate using Bio-Plex Manager software
(vers 6.1). Soluble TNF-α receptors (TNF-RI and TNF-
RII) was carried out using a solid-phase enzyme-linked
immunosorbent assay method (ELISA) based on the
quantitative immunometric sandwich enzyme immuno-
assay technique following the manifacture instruction
(R&D Systems, Abingdon, UK). The intra-plate CV% was
less than 4.8, while the inter-plate CV% was less than 5.1
for these assays. Plasma samples from 10 healthy volun-
teers were used as controls.
Statistical analysis
In view of the inherent variation in absolute cytokine con-
centrations between patients, the median value for each
cytokine was chosen for univariate analyses. Continuous
data are presented as mean and standard deviation (SD)
or median and interquartile range (IQR) depending on
data distribution, while categorical data are presented as
rate and proportion. Correlation between each cytokine
and different secondary insults expressed as proportion of
GMT was performed by linear regression analysis; differ-
ences among demographic data and cytokines level in the
three outcome categories were tested using analysis of
variance (ANOVA) or chi-squared test as appropriate and
considered significant for p < 0.05. If ANOVA was signifi-
cant, post-hoc analysis by Bonferroni was applied.
Multivariate projection is a data reduction technique
that allows the major sources of variation in a multi-
dimensional dataset to be analysed without introducing
inherent bias. Principal component analysis (PCA) is
used to identify principal components which account for
the majority of the variation within the dataset. Number
of principal components have been identified using Kaiser
criteria (Eigenvalue >1).
Partial least squares (PLS) is a linear predictive model to
maximize both the variation within the dataset and to the
response variable. For multivariate projection techniques
all cytokines values (T0, T1, T2 and T3) have been used
after log-tranformation. The most significant cytokines in
the PLS model were identified by the Variable Importance
Projection (VIP). VIP is a measure of a variable’s import-
ance in modeling both variation of cytokines, explained by
each partial least squares factor, and variation of raised
ICP insult. If a variable has a small coefficient and a small
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VIP (<0.8 -Wold’s criterion), then it is a candidate for de-
letion from the model.
In our study, PCA was applied to explore any intrinsic
variation in the cytokine dataset while PLS was used to
test the correlation between raised ICP (response vari-
able) and cytokines. Finally, a multinomial generalized
equation estimated (GEE) logistic regression model was
applied to verify the predictive value of the principal
components adjusted for clinical variables on neuro-
logical outcome. In order to correct for repeated mea-
surements a robust sandwich standard error estimate
was used. (SAS vers 9.3).
Results
Clinical data and occurrence of secondary insults
Twenty nine adult severe TBI patients (25 males and 4
females) were enrolled in the study. Demographic data
of patients classified according to neurological outcome
are presented in Table 1. Three patients presenting at
admission with a GCS > 8 where included in the study as
they suddenly deteriorated and met inclusion criteria.
Difference in admission characteristics among favorable,
unfavorable outcome at 6 months and brain-dead pa-
tients were not significant. Seventeen of the 29 enrolled
patients suffered a polytrauma. The severity of trauma,
assessed by ISS revealed a serious injury (ISS 9–15) in
thre patients, a severe injury (ISS 16–24) in four pa-
tients, and a critical injury (ISS 25–75) in 22 patients.
Five patients evolved to brain death within the first
3 days. GOSe at 6 months revealed: seven deaths includ-
ing brain death (24 %), one persistent vegetative state
(3 %), six upper or lower severe disability (21 %), eigth
upper or lower moderate disability (28 %), seven lower
or upper good recovery (24 %).
Median duration of GMT in the studied population
was 7350 min (range 1191–13040). Occurrence of sec-
ondary insults during early phase of ICU stay, expressed
as proportion of GMT for each grade, in each insult cat-
egory is presented in Fig. 1. Raised ICP insult occurred
in 21.9 % of GMT (CI 10.96; 32.75), low CPP insult in
Table 1 Demographic data of the patient population in the three outcome groups (n = 29 Patients)
Variables Favorable outcome 6Ma Unfavorable outcome 6Ma Brain death
n = 15 n = 9 n = 5
Age (years), mean (SD) 35.9 (16.6) 40.8 (23.3) 42.2 (19.8)
Apache II, mean (SD) 14.1 (3.6) 15.6 (2.6) 16.6 (2.3)
GCS, median (IQR) 6 (3; 8) 4 (3; 5) 3 (3; 4)
GCSm, median (IQR) 4 (1; 4) 2 (1; 3) 1 (1; 1)
Marshall, median (IQR) 3 (2; 5) 3 (3; 5) 5 (4; 5)
Isolated TBI, n (%) 6 (40) 3 (33) 3 (60)
TBI in politrauma, n (%) 9 (60) 6 (67) 2 (40)
ISS, mean (SD) 27.5 (12.3) 28.3 (10.6) 26.2 (1.8)
AIS head, median (IQR) 4 (3; 4) 4 (3; 5) 5 (4; 5)
Focal injury, n (%) 4 (27) 3 (33) 3 (60)
Diffuse injury, n (%) 11 (73) 6 (67) 2 (40)
Main intracranial lesion, n (%)
Epidural hematoma 2 (13) 0 (0) 1 (20)
Subdural hematoma 1 (7) 2 (22) 3 (60)
Traumatic subarachnoid hemorrhage 3 (20) 1 (11) 0 (0)
Contusions 7 (47) 2 (22) 1 (20)
Intracerebral mass lesion 1 (7) 2 (22) 0 (0)
Brain swelling 1 (7) 1 (11) 0 (0)
Diffuse axonal injury 0 (0) 1 (11) 0 (0)
Mechanism of injury, n (%)
Fall 7 (47) 3 (33) 4 (80)
Motor vehicle collision 3 (20) 2 (22) 0 (0)
Motorcycle 1 (7) 3 (33) 1 (20)
Bicycle crash 2 (13) 0 (0) 0 (0)
Pedestrian 2 (13) 1 (11) 0 (0)
aAt 6 months. GCS Glasgow coma scale, GCSm Glasgow coma scale, motor score, TBI traumatic brain injury, ISS injury severity score, AIS abbreviated injury scale
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21.1 % (CI 11.69; 30.59), pyrexia insult in 14.2 % (CI 9.23;
19.19), hypotension insult in 9.5 % (CI 4.61; 14.41) and
hypoxia insult in 1.5 % (CI 0; 3.61). The majority of insults
were of grade 1 and occurred in 11.9, 11.1, 13.8, and 7.9 %
of GMT for raised ICP, low CPP, pyrexia and hypotension
insult, respectively. Hypoxia insult in the early phase of
ICU was rare but severe (grade 3). Median and range of
secondary insults duration in the studied population were:
raised ICP insult equal to 833 min (range 0–3513), low
CPP insult equal to 904 (0–4095), pyrexia insult equal to
660 (0–3329), hypotension insult equal to 258 (0–2242),
hypoxia insult equal to 0 (0–1637).
Relationship between plasma cytokines level and
secondary insults
A several-fold variation in the cytokine concentrations re-
covered was observed among patients. All cytokines were
detectable in the analysed samples and increased from
control levels while IL-2, MIP1α, IL-15, IL-17, and basic
FGF were under detection limit in several patients. To
deal with the repeated measures obtained from T0 to T3,
we presented cytokines as median values over time. One
patient died at T1 and had only two determinations.
Il-6, IL-2, Il-10, IL-12, IL-15, VEGF, and MIP1β
were the cytokines with the strongest correlation
with secondary insults (R2 > 0.5 and p < 0.01). IL-6,
IL-15 and VEGF were associated with ICP and low
CPP insult, MIP1β with CPP insult, and IL-2, IL-10,
and IL-12 with hypoxia insult (Fig. 2). IL-6 was the
most important cytokine associated with raised ICP
(R2 = 0.574, p < 0.0001) and low CPP insult (R2 = 0.587,
p = 0.0001) (Fig. 3). All the correlations were confirmed
when absolute numbers of minutes of insults were con-
sidered for analysis.
Correlations were found between plasma cytokine
levels and demographic or severity scores at admission:
age correlated with TNF-RI (R2 = 0.224, p = 0.009),
TNF-RII (R2 = 0.270, p = 0.004) and VEGF (R2 = 0.129,
p = 0.05); GCS motor score (GCSm) correlated with
basicFGF (R2 = 0.146, p = 0.041), GCSF (R2 = 0.132, p =
0.05) and IP-10 (R2 = 0.167, p = 0.028); APACHE II score
correlated with IP-10 (R2 = 0.154, p = 0.035), MIP1β (R2 =
0.134, p = 0.05), TNF-RII (R2 = 0.257, p = 0.005), and VEGF
(R2 = 0.161, p = 0.031); Marshall scale correlated with
IL-7 (R2 = 0.131, p = 0.05), IL-13 (R2 = 0.130, p = 0.05),
IP-10 (R2 = 0.157, p = 0.033), and VEGF (R2 = 0.153,
p = 0.036).
Fig. 1 Occurrence of secondary insults, expressed as proportion of good monitoring time (GMT), for each insult category and each grade of
severity. ICP intracranial pressure, CPP cerebral perfusion pressure. Tags inside bars indicate proportion of GMT for each insult grade
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Relationship between plasma cytokine levels and
neurological outcome
Median plasma cytokine levels were significantly higher
in patients evolving to brain death when compared to
the other two groups (Table 2). Raised ICP, hypotension,
low CPP, hypoxia insults (Fig. 4a) and IL-6 level (Fig. 4b)
were significantly (p < 0.05) higher in patients early
evolving to brain death compared to both patients with
unfavorable and favorable outcome at 6 months.
Multivariate projection method
PCA was performed to examine the presence of covari-
ance in the cytokine dataset. According to Kaiser criteria,
the first five PCs generated by the model explained 72 %
of the cumulative variation within the dataset. Figure 5a
shows the scores plot for each observation of PC1 and
PC2 which explained 53 % of the cumulative variation
within data set. The ellipse on the plot (Hotelling ellipse)
represents the 95 % CI for the model and no outlier was
detected. The loading plot (Fig. 5b) illustrates the relative
contribution of each cytokine to the two PCs. The first
component was strongly correlated with the following cy-
tokines: GCSF, IL-4, IL-12, IL-10, basic FGF, IL-17, IFNγ,
IL-8, MIP1α, VEGF, IL-1ra, IL-9, IL-7, PDGFbb, IP10,
RANTES, IL-13, and IL-5. The second component was
strongly correlated with IL-6, MIP1β, TNF-RII, Eotaxin,
TNF-RI, MCP1, and IL-15. IL1β and TNFα were the cyto-
kines which showed the highest coefficient of correlation
within the third principal component; that explained the
8 % of variation within the dataset.
Overall PLS analysis including the first five factors ex-
plained 63 % of cytokines variation and 53 % of raised
ICP. According to the Wold’s criterion, in the PLS analysis
IL-6, basic FGF, MIP1α, RANTES, IP10, MIP1β, explained
most of the variation in the dataset and were the most
powerful predictors for raised ICP (Fig. 6a and b).
To verify the predictive power of cytokine data on
neurological outcome, the first two PCs, which explained
most of the variability in the dataset, were entered in the
multinomial logistic regression model together with
demographic clinical variables (age, GCSm and Marshall
score). GCSm was a powerful predictor discriminating
patients with favorable outcome versus those who early
died because of brain death. The first two PCs were sig-
nificant predictors discriminating patients with favorable
outcome versus both brain dead (OR = 1.91 [1.24; 2.94]
and 4.64 [1.79; 12.05]) and unfavorable outcome (OR =
1.80 [1.34; 2.42] and 1.62 [1.02; 2.59], for PC1 and PC2
respectively, Table 3). The odds to evolve in brain death
rather than favorable outcome increased 91 % for each
unit increase in PC1.
Discussion
In this pilot study, we used a multivariate projection
technique to identify distinct pattern of inflammatory re-
sponse in TBI patients suffering of secondary insults.
With this methodology, we demonstrated that patients
who suffered from prolonged and severe secondary brain
damage were characterized by a specific pattern of cyto-
kines. Interestingly, in patients early evolving to brain
death higher levels of inflammatory mediators were de-
tected compared to both patients with long term favor-
able and unfavorable outcome. Keeping in mind the
relatively small number of patients, the large number of
cytokines and their putative statistical interactions, we
applied the PCA to objectively identify the most relevant
Fig. 2 Linear regression analysis between median plasma levels of cytokines and secondary insults. The results are presented as percentage of R
square between cytokines and secondary insults. R2 > 0.5 and p < 0.01 are red colored. ICP intracranial pressure, CPP cerebral perfusion pressure
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Fig. 3 Linear regression analysis between median plasma levels of IL-6 and proportion of raised ICP a and low CPP b insults. Insults are expressed
as proportion of good monitoring time (GMT). Grey shadow represents 95 % confidence limits. Dotted lines represent 95 % prediction limits. ICP
intracranial pressure, CPP cerebral perfusion pressure
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molecules in the early phase after TBI. The first 2 princi-
pal components explained 72 % of the variation within
the dataset and were independently associated with poor
neurological outcome. In the two components, the most
relevant proinflammatory cytokines (GCSF, IL-6, IL-15),
anti-inflammatory cytokines (IL-10, IL-1ra), chemokines,
and growth factors (basicFGF, MIP1α, MIP1β, VEGF)
were recognised by high coefficients. The PLS analysis
identified IL-6, basic FGF, MIP1α, MIP1β, RANTES and
IP10, as the main cytokines able to explain most of the
variation in the dataset and to predict raised ICP.
Detrimental effects of secondary insults on TBI progno-
sis has been extensively investigated, but the exact
mechanism leading to the exacerbation of brain damage
remains unclear. Post-traumatic neuroinflammation, pro-
posed as a potential mechanism of damage and repair, is
characterised by glial activation, leukocyte recruitment
and upregulation and secretion of mediators such as cyto-
kines and chemotactic cytokines (chemokines) [3, 21, 22,
33, 34]. Inflammatory mediators have been measured in
plasma, CSF and in brain microdialysate, suggesting a
cerebral production of pro and anti-inflammatory cyto-
kines [9]. In cases of brain injury complicated by multiple
traumas, plasmatic levels of inflammatory mediators may
reflect the effect of peripheral immune response [7]. In-
deed recently Santarsieri et al. [6], demonstrated an asso-
ciation between CSF levels of inflammatory mediators in
the first 6 days after injury and outcome modulated by
Table 2 Median plasma level of inflammatory mediators in the 3 outcome groups
Favorable outcome 6Ma Unfavorable outcome 6Ma Brain death p value
IL-6 75.08 (31.81; 104.76) 169.95 (79.17; 188.3) 750 (602; 817) <0.0001
IL-1β 0.66 (0.1; 1.05) 1.04 (0.6; 5.78) 1.32 (1.1; 1.97) 0.179
IL-1ra 66.92 (34.68; 226.97) 82.02 (70; 384.13) 532.66 (399; 2078.5) 0.078
IL-2 0.8 (0.8; 0.8) 0.8 (0.8; 0.8) 0.8 (0.8; 29.5) 0.041
IL-4 0.21 (0.01; 1.32) 0.6 (0.42; 5.31) 0.93 (0.8; 1.34) 0.304
IL-5 0.85 (0.13; 5.24) 1.14 (0.28; 15.36) 0.5 (0.29; 0.62) 0.415
IL-7 9.27 (1.38; 31.41) 45.4 (7.23; 141.17) 58.98 (16.25; 92.5) 0.215
IL-8 19.39 (3.99; 39.64) 60.29 (39; 104.58) 125.55 (37.02; 129) 0.013
IL-9 12.13 (2.35; 20.13) 32.91 (28; 46.86) 23.68 (20.5; 48.26) 0.022
IL-10 11.52 (1.57; 20.14) 20 (7.83; 57.02) 39.47 (12.37; 108.5) 0.029
IL-12 5.64 (0.81; 22.2) 11.82 (5.33; 42.48) 20.15 (17; 109.5) 0.043
IL-13 2.97 (0.62; 5.27) 7.4 (1.92; 11.27) 12.06 (5.78; 30) 0.047
IL-15 1.05 (0.06; 4.6) 0.06 (0.06; 6.16) 22.75 (3.7; 44.9) 0.001
IL-17 0.9 (0.9; 9.58) 49.06 (0.9; 75.33) 67.84 (28; 77.42) 0.162
Eotaxin 0.35 (0.35; 18.45) 19 (0.35; 29.31) 24.49 (10.5; 34.42) 0.094
basic FGF 3 (3; 24.45) 48.73 (3; 66.79) 49.61 (49.49; 131) 0.053
GCSF 50.95 (8.99; 138.65) 156.61 (107.5; 368.77) 483.17 (165; 491.86) 0.012
GMCSF 48 (2.29; 78.14) 39.18 (0.21; 91.61) 99.55 (83.84; 113) 0.084
IFNγ 4.15 (1.08; 25.73) 14.97 (11.99; 110.33) 25 (24.74; 29.08) 0.230
IP-10 111.06 (29; 256.19) 248.22 (215.09; 459.34) 2081.5 (528.43; 2232.08) <0.0001
MCP1 162.16 (44.12; 307.83) 196.04 (77.78; 657.25) 690.82 (600; 2210) 0.001
MIP1α 1.5 (0.05; 2.33) 3.07 (1.2; 6.49) 3.71 (0.05; 11) 0.209
PDGFbb 141.57 (58.58; 229.67) 271.36 (195.11; 372.25) 104.64 (93.1; 210.46) 0.324
MIP1β 87.27 (55.98; 134.88) 123.05 (98; 133.01) 416 (275.42; 594) 0.001
RANTES 5193.61 (1952.35; 8553.06) 8903.57 (4098.28; 11442.69) 3570.05 (2309.71; 3831.31) 0.564
TNF-RI 1252.27 (522.38; 1568.18) 1320.45 (970.33; 1513.64) 1957 (1543.13; 2679) 0.394
TNF-RII 2190 (730; 4723.08) 4161.9 (3707.69; 5368.54) 5678 (4919; 6564.78) 0.021
TNFα 8 (5.58; 50.59) 5.5 (3.9; 93.05) 9.78 (8.12; 18.45) 0.262
VEGF 6.04 (0.08; 27.12) 29.79 (8.12; 42.22) 60.22 (34.28; 322) 0.002
IL6/IL10 57 (30.39; 324.61) 59.24 (39.89; 104.28) 277.07 (126.7; 1598.89) 0.765
IL1ra/IL1β 7.92 (3.66; 19.53) 8.9 (3.77; 22.4) 27.11 (5; 32.29) 0.064
aAt 6 months. Values are median (IQR). IQR interquartile range. Significant correlations are reported in italics
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Fig. 4 The incidence of secondary insults, expressed as proportion of good monitoring time (GMT) is described in each outcome group (a). Difference
among groups was significant for raised ICP, hypotension, low CPP, and hypoxia insults (ANOVA, p < 0.01). Post-hoc analysis revealed that differences
were significant between brain death and both favorable and unfavorable outcome (*p < 0.05). Data are expressed as mean and standard error.
ICP intracranial pressure, CPP cerebral perfusion pressure. b Boxplots of IL-6 level in each outcome group. Difference among groups was significant
(ANOVA, p < 0.001). Post-hoc analysis revealed that differences were significant between brain death and both favorable and unfavorable outcome
(*p < 0.05). Circles represent outliers
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cortisol levels. Recent experimental and clinical investiga-
tions data have also documented the role of microglia as
source and target of inflammatory response [10, 35].
Cytokines produced by different CNS cells may have
both beneficial and detrimental roles. Clear benefit can be
achieved if the inflammation is controlled in a regulated
manner and for a defined period of time; when sustained
or excessive, however, inflammation is detrimental [36].
Unfortunately conflicting results have been reported on
the role of different cytokines as repair mechanisms or ex-
acerbation of the pathophysiology of brain trauma.
IL-6 is a multifunctional factor widely investigated in
both experimental and clinical studies. Hergenroeder et al.
[21] found that serum IL-6 levels within the first 24 h
were significantly higher in patients who developed high
ICP compared with patients with normal ICP. Minambres
et al. [25] demonstrated that transcranial IL-6 gradient at
admission correlated with poor prognosis at 6 months,
Fig. 5 Panel a: Scores plot shows the scores on each principal component for each observation. The ellipse on the plot (Hotelling ellipse) is the 95 %
CI for the model. b Loading plot shows the cytokines which load on the respective principal components. Cytokines which better explain Principal
Components 1 and 2 are marked in red and green, respectively
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and was significantly higher in patients evolving to
brain death. Conversely Perez-Barcena et al. [37] did
not identify a clear relationship between the temporal
profile of IL-6 and ICP elevation, brain tissue oxygen-
ation and the presence of brain swelling on CT scan.
More recently, Kumar et al. using the group-based tra-
jectory analysis demonstrated that patients with a high
CSF IL-6 trajectory profile had worst outcome [5].
IL-1 cytokine family has been described as an important
determinant of inflammation: IL-1α and IL-1β appear
pro-inflammatory, while the endogenous IL-1ra appears
anti-inflammatory. Thus elevation of IL-1ra/IL-1β ratio is
seen as an anti-inflammatory indicator and in an elegant
microdialysis study has been shown to be associated with
better outcome [34, 38].
Chemokines contribution to secondary injury is medi-
ated by accumulation of active leukocytes that perpetuates
inflammation and neurotoxic cascades. In an observa-
tional clinical study the occurrence of hypoxemia after
TBI was not associated with increased levels of IL-2, IL-6,
Fig. 6 Panel a shows the variable importance projection (VIP) scores. A VIP score is a measure of a variable’s importance in modeling both
variation of cytokines and variation of raised ICP insult. A value of 0.8 is generally considered to be a small VIP and a line is drawn on the plot at
0.8. Panel b is a regression coefficient profile indicating which cytokines better predict raised ICP insult. The regression coefficients represents the
importance that each cytokine has in the prediction of raised ICP insult
Mazzeo et al. Journal of Neuroinflammation  (2016) 13:157 Page 11 of 15
and IL-10 but only with GM-CSF, S100 and myelin basic
protein levels measured in CSF [24] while Stein et al. dem-
onstrated that TNF-α and IL-8 were good predictors of
both high ICP and low CPP recorded hourly by the chart
[22, 33]. Recently Di Battista et al. [7] demonstrated the
association between elevated IL-8, IL-10, TNF-α, MIP 1β,
and MCP-1, hyperadrenergic state and poor outcome.
The differences in study design, time window, and param-
eters analysed may account for much of the variability in
these results.
Recently, the Wagner group [5] suggested that individ-
ual inflammatory markers may not be as informative of
TBI pathology or predictive of outcome as an aggregated
inflammatory score. In this perspective, they proposed a
novel cytokine load score (CLS) and found a persistent
inflammatory state with elevated serum IL-1β, IL-6, IL-
8, IL-10, and TNFα levels over the first year post-injury,
possibly as a result of a spillover effect from acute eleva-
tion after TBI; the proposed CLS was predictive of out-
come at 6 and 12 months [5].
The main limitation in studies on neuroinflammation
is indeed that authors mainly investigated the relation-
ship between “a priori” selected cytokines and clinical
variables, such as intracranial hypertension, hypoxemia
or the prognostic value of these mediators. In these
studies univariate correlations between a given mediator
and a clinical outcome was applied to draw inferences
regarding the biological action of the selected cytokine.
From the pathophysiological point of view, this approach
may be flawed because the primary injury is the com-
mon trigger for cytokines production and therefore is
likely that these mediators will correlate with each other,
particularly those cytokines that are directly antagonistic
to one another at the same receptor.
The possible multiple collinearity among variables can
be managed by data reduction methods but to prevent
overfitting, large numbers of subjects in relation to the
number of variables are required. Disentangling the pro-
file and the inter-relationship between these mediators
and avoiding the “a priori” selection of the potential rele-
vant molecules is crucial to investigate their mechanistic
role in the pathophysiology of TBI.
To overcome the problem of multiple variables with
putative statistical interactions, multivariate projection
techniques have been recently proposed. Helmy et al.
used the PCA [8] to simplify multivariate data into few
PCs that contains the main sources of variation within
the dataset as a whole. These PCs are made up of a lin-
ear combination of the original variables, each of which
contributes to a varying degree, termed the “loading”.
The first PC is a linear combination of each of the ori-
ginal variables which incorporate the greatest source of
variation within the dataset and will have a larger magni-
tude of coefficient than those contributing to a lesser
degree. The second and subsequent PCs are further
variables that explain the greatest sources of variation
left over beyond the first PC. This analysis was used by
Helmy et al. to demonstrate the different pattern of
response in brain and peripheral blood of cytokines
production and to demonstrate difference in cytokines
profile after recombinant human IL-1ra administration
in a phase II randomized control trial [10, 38].
In coherence with previous literature, in our study Il-
6, IL-1ra, Il-8, IL-10, IL-15, MCP-1, MIP-1β, and IP10
were selected in the first two components of PCA as
strong predictors of outcome confirming their role in
the pathophysiology of brain injury. Among them IL-6,
IP10, and MIP-1β remained in the predictive model for
raised ICP. PCA analysis has also been recently used by
Kumar et al. to explore the pattern of markers that con-
tribute independently to variability in CSF inflammatory
response. They found that Il-1β and TNFα provided
limited contribution to variance suggesting that even if
elevated, these markers had low discriminative capacity
in inter-individual variability after TBI [5].
In our study, we collected data from ICU admission
for the first 5 days and included also multiple trauma
patients. It is therefore possible that an inflammatory re-
sponse occurring within few hours from injury or after
the first 5 days was missed in our database. Finally, the
coexisting multiple trauma may have affected the extent
of systemic inflammatory response in our patients and
their impact on outcome.
Table 3 Multinomial logistic regression model of neurological
outcome
Variables OR [CI 95 %] vs favorable outcome p value
Age
Brain dead 0.96 [0.91; 1.02] 0.226
Unfavorable 0.98 [0.93; 1.04] 0.523
Marshall
Brain dead 1.27 [0.28; 5.81] 0.762
Unfavorable 1.18 [0.46; 3.04] 0.730
GCSm
Brain dead 0.37 [0.16; 0.85] 0.018
Unfavorable 0.98 [0.48; 2.01] 0.958
Principal component 1
Brain dead 1.91 [1.24; 2.94] 0.003
Unfavorable 1.80 [1.34; 2.42] <0.0001
Principal component 2
Brain dead 4.64 [1.79; 12.05] 0.002
Unfavorable 1.62 [1.02; 2.59] 0.041
GCSm Glasgow Coma Scale, motor score. Unfavorable = unfavorable outcome
at 6 months
Brain dead = brain dead patients
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A novel aspect of our study is related to the rigorous
methodology that we used to record and collect secondary
insults occurring early after ICU admission. In TBI pa-
tients following the initial event, secondary insults such as
high ICP, low CPP, hypoxemia and pyrexia amplify the
secondary damage and have been widely demonstrated to
affect outcome. We resorted to the EUSIG scale proposed
by Miller et al. [18] which is based on physiological
thresholds to quantify occurrence and severity of second-
ary insults [13]. As part of the BrainIT group [27] in the
present study, we collected high quality minute-by-minute
physiological monitoring data using a standardized data
collection equipment. Raised ICP and low CPP were the
most frequent secondary insults occurring in almost 21 %
of GMT. These results are consistent with literature, with
intracranial hypertension occurring in 5–39 % of monitor-
ing time depending on systems used to capture the insults
and applied thresholds [28, 39, 40]. The strong predictive
power of raised ICP on neurological outcome has been
further confirmed by Güiza et al. [41]. Pyrexia occurred in
14 % of GMT, similarly to data reported with the same
methodology [13, 42]. The occurrence of hypoxemia was
rare (1.5 % of GMT) in our study, since patients were in-
cluded after initial ICU stabilization. In the present study
we separately analysed those patients who died because of
brain herniation from those who had a poor outcome at 6
months. Those who evolved to brain death clearly repre-
sented the group with the worst secondary insults. Indeed
intracranial hypertension was present for almost 70 % of
the GMT. On the other hand, in the same time window,
occurrence of secondary insults was not significantly dif-
ferent between patients with favorable and unfavorable
outcome at 6 months. This result suggests that different
factors such as late secondary insults [43] and non neuro-
logical complications may play a major role in determin-
ing long-term neurological outcome [44].
Due to the observational design of the study, we were
not able to conclude if the inflammatory reaction should
be considered as marker of severity or mediator of the
secondary insults. However the multivariate projection
method identified a specific pattern of inflammation over-
coming putative interactions and avoiding any subjective
selection of relevant molecules.
Conclusions
With the use of multivariate projection method, we
showed that patients with severe TBI were character-
ized by a specific pattern of inflammatory reaction as-
sociated with the occurrence of raised ICP. This
pattern of cytokines was selected by the PCA as power-
ful predictor of both the conditions of unfavorable out-
come and early brain death. Even if this preliminary
analysis requires confirmation in larger studies, our results
shed more light on the correlation between secondary
insults, systemic inflammation and neurological outcome
after TBI, and may help in the future to identify specific
therapeutic targets that modulate inflammation.
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